| Metric | H1 FY27 | H2 FY26 | H1 FY26 |
|---|---|---|---|
| Revenue from operations | 55.0 | 45.9 | 43.7 |
| Other income | 0.1 | 0.1 | 0.1 |
| Total income | 55.2 | 46.0 | 43.8 |
| Profit before exceptional items & tax | 10.8 | 6.7 | 6.4 |
| Profit before tax | 10.8 | 6.7 | 6.4 |
| Net profit | 8.2 | 4.9 | 4.8 |
| Operating margin | 19.6% | 14.6% | 14.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +70.80% |
|---|---|
| Net profit, quarter on quarter | +67.30% |
| Revenue, year on year | +25.90% |
| Operating profit, year on year | +69.80% |
| Operating profit, quarter on quarter | +62.10% |
NSE results filing, NSE: ACCPL. Figures extracted from the filing.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹190.05
- Market cap
- ₹211.3 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 21.9×Sector 45.9×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited announced the results of its postal ballot, where shareholders approved five special resolutions, including increasing borrowing limits and charging company assets.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited held its 3rd Annual General Meeting on August 27, 2026. The meeting transacted business including the adoption of financial statements and director re-appointment.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited has provided the web link for shareholders to access its Annual Report for FY 2025-26 and the 3rd AGM notice.